Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics

Genome Research

Volumn 22, Issue 11, 2012, Pages 2089-2100

  Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; ELONGIN B; ELONGIN C; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FUMARATE HYDRATASE; HAMARTIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PAZOPANIB; RAPAMYCIN; SUCCINATE DEHYDROGENASE; TEMSIROLIMUS; TUBERIN; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; BIRT HOGG DUBE SYNDROME; CANCER GENETICS; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 2; CHROMOSOME 3; CHROMOSOME 6; CHROMOSOME 8; CHROMOSOME TRANSLOCATION; COMPUTER ASSISTED TOMOGRAPHY; ENERGY YIELD; FATTY ACID SYNTHESIS; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC LINKAGE; GENETIC RISK; GLYCOLYSIS; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; METABOLIC DISORDER; METASTASIS; METHYLATION; OXYGEN SENSING; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; TUBEROUS SCLEROSIS; X CHROMOSOME;

ANTINEOPLASTIC AGENTS; CARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; KIDNEY NEOPLASMS; MUTATION;

EID: 84868309625     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.131110.111     Document Type: Review

References (100)

1. Anglard P, Brauch TH, Weiss GH, Latif F, Merino MJ, Lerman MI, Zbar B, Linehan WM. 1991. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 51:1071-1077.
2. Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB, Perlman EJ. 2001. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 158:2089-2096.
3. Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, Reuter VE, Netto GJ. 2010. Xp11 translocation renal cell carcinoma (RCC): Extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 34:1295-1303.
4. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF III, Hartley JL, et al. 2006. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci 103:15552-15557.
5. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, et al. 2008. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 100:140-154.
6. Beroukhim R, Brunet JP, Di NA, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et al. 2009. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69:4674-4681.
7. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, et al. 2011. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94-98.
8. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. 2008. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151.
9. Chernoff A, Choyke PL, Linehan WM, Walther MM. 2001. Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. J Urol 165:1623-1624.
10. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. 2012. A phase II and biomarker study of the dual MET/VEGFR-2 inhibitor foretinib in patients with papillary renal-cell carcinoma. J Clin Oncol (in press).
11. nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15:2233-2239.
12. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS. 1979. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592-595.
13. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med 355:1345-1356.
14. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463:360-363.
15. Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, et al. 2003. Cloning of an a-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci 100:6051-6056.
16. Delahunt B, Eble JN. 1997. Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537-544.
17. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406.
18. Eleveld MJ, Bodmer D, Merkx G, Siepman A, Sprenger SH, Weterman MA, Ligtenberg MJ, Kamp J, Stapper W, Jeuken JW, et al. 2001. Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). Genes Chromosomes Cancer 31:23-32.
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134.
20. Fadahunsi AT, Sanford T, Linehan WM, Pinto PA, Bratslavsky G. 2011. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol 185:49-53.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
22. Gad S, Lefevre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V, Ferlicot S, Molinie V, Denoux Y, Thiounn N, et al. 2007. Mutations in BHD and TP53 genes, but not in HNF1b gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 96:336-340.
23. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892.
24. Gill AJ, Pachter NS, Clarkson A, Tucker KM, Winship IM, Benn DE, Robinson BG, Clifton-Bligh RJ. 2011. Renal tumors and hereditary pheochromocytoma- paraganglioma syndrome type 4. N Engl J Med 364:885-886.
25. Gnarra JR, Tory K, Weng Y, Schmidt LS, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90.
26. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, Torres-Cabala C, Glenn GM, Choyke P, Merino MJ, et al. 2007. Hereditary leiomyomatosis and renal cell cancer: A syndrome associated with an aggressive form of inherited renal cancer. J Urol 177:2074-2080.
27. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, Hardarson S, Magnusson K, Gulcher J, Stefansson K, et al. 2002. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 100:476-479.
28. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS. 2008. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415:60-67.
29. Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, et al. 2009. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci 106:18722-18727.
30. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci 91:9700-9704.
31. Herring JC, Enquist EG, Chernoff A, Linehan WM, Choyke PL, Walther MM. 2001. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma:10-year experience. J Urol 165:777-781.
32. Hosoe S, Brauch H, Latif F, Glenn GM, Daniel L, Bale S, Choyke P, Gorin M, Oldfield E, Berman A, et al. 1990. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8:634-640.
33. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. 2007. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281.
34. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino MJ, Trepel J, Zbar B, Toro J, et al. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-153.
35. 2- regulated prolyl hydroxylation. Science 292:468-472.
36. 2 sensing and cancer. Nat Rev Cancer 8:865-873.
37. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, et al. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661.
38. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444-1446.
39. Knudson AG. 1995. VHL gene mutation and clear-cell renal carcinomas. Cancer J 1:180-181.
40. Latif F, Tory K, Gnarra JR, Yao M, Duh F-M, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
41. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA. 2001. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci 98:3387-3392.
42. Leroy X, Zini L, Leteurtre E, Zerimech F, Porchet N, Aubert JP, Gosselin B, Copin MC. 2002. Morphologic subtyping of papillary renal cell carcinoma: Correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 15:1126-1130.
43. Linehan WM, Zbar B. 2004. Focus on kidney cancer. Cancer Cell 6:223-228.
44. Linehan WM, Walther MM, Zbar B. 2003. The genetic basis of cancer of the kidney. J Urol 170:2163-2172.
45. Linehan WM, Srinivasan R, Schmidt LS. 2010. The genetic basis of kidney cancer: A metabolic disease. Nature Reviews Urology 7:277-285.
46. Linehan WM, Yang JC, Rini B. 2011. Cancer of the kidney. In Cancer: Principles and practice of oncology (ed. VT DeVita et al.), pp. 1161-1182. Lippincott Williams & Wilkins, New Haven, CT.
47. Lonser RR, Glenn GM, Walther MM, Chew EY, Libutti SK, Linehan WM, Oldfield EH. 2003. von Hippel-Lindau disease. Lancet 361:2059-2067.
48. Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, et al. 2004. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 23:40-46.
49. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
50. Merino MJ, Torres-Cabala C, Pinto PA, Linehan WM. 2007. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31:1578-1585.
51. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, et al. 2012. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380-384.
52. Meyer JR, Dobias DT, Weitz JS, Barrick JE, Quick RT, Lenski RE. 2012. Repeatability and contingency in the evolution of a key innovation in phage l. Science 335:428-432.
53. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, et al. 2011. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 7:1-13.
54. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
55. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, et al. 2008. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:1432-1439.
56. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. 2011. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481:385-388.
57. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, et al. 2004. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951.
58. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn GM, Turner ML, Duray P, Merino MJ, Choyke P, Pavlovich CP, et al. 2002. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157-164.
59. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, et al. 2008. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14:4726-4734.
60. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the b-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427.
61. Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM. 2000. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol 163:431-433.
62. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ. 2008. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123:395-400.
63. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. 2002. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 26:1542-1552.
64. Pavlovich CP, Grubb RL, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, et al. 2005. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173:1482-1486.
65. Podolski J, Byrski T, Zajaczek S, Druck T, Zimonjic DB, Popescu NC, Kata G, Borowka A, Gronwald J, Lubinski J, et al. 2001. Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet 46:685-693.
66. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, et al. 2011. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43:60-65.
67. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F, Maher ER. 2008. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260-1262.
68. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. 2011. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939.
69. Schmidt LS, Li F, Brown RS, Berg S, Chen F, Wei MH, Tory K, Lerman I, Zbar B. 1995. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1:191-195.
70. Schmidt LS, Duh FM, Chen F, Kishida T, Glenn GM, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
71. Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al. 1999. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350.
72. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. 2010. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068.
73. Stolle C, Glenn GM, Zbar B, Humphrey JS, Choyke P, Walther MM, Pack S, Hurley K, Andrey C, Klausner R, et al. 1998. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423.
74. Takahashi M, Sugimura J, Yang X, Vogelzang N, Teh BS, Furge K, Teh BT. 2003a. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res 89:157-181.
75. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, et al. 2003b. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22:6810-6818.
76. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410.
77. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, et al. 2011. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20:315-327.
78. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, et al. 2003. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95-106.
79. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke CD, Turner M, Choyke P, Merino MJ, Pinto PA, et al. 2008. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: A new series of 50 families and a review of published reports. J Med Genet 45:321-331.
80. Van Erp F, Van Ravenswaaij C, Bodmer D, Eleveld M, Hoogerbrugge N, Mulders P, Geurts K. 2003. Chromosome 3 translocations and the risk to develop renal cell cancer: A Dutch intergroup study. Genet Couns 14:149-154.
81. Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peczkowska M, Morrison CD, Lehtonen R, Januszewicz A, Jarvinen H, Juhola M, et al. 2004. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74:153-159.
82. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al. 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542.
83. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, et al. 2003. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci 100:6958-6963.
84. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM. 2005. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931-935.
85. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. 1988. Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532.
86. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. 1995. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 154:2010-2014.
87. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, et al. 2010. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327:1004-1007.
88. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314.
89. Warburg O, Posener K, Negelein E. 1924. Metabolism of the carcinoma cell. Biochem Z 152:309-344.
90. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, et al. 2006. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43:18-27.
91. Yang JC. 2004. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10:6367S-6370S.
92. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434.
93. /FH~) hereditary leiomyomatosis renal cell carcinoma: In vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 196:45-55.
94. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, et al. 2009. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15:7582-7592.
95. Zbar B, Brauch H, Talmadge C, Linehan WM. 1987. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721-724.
96. Zbar B, Tory K, Merino MJ, Schmidt LS, Glenn GM, Choyke P, Walther MM, Lerman M, Linehan WM. 1994. Hereditary papillary renal cell carcinoma. J Urol 151:561-566.
97. Zbar B, Glenn GM, Lubensky IA, Choyke P, Magnusson G, Bergerheim U, Pettersson S, Amin M, Hurley K, Linehan WM, et al. 1995. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol 153:907-912.
98. Zbar B, Alvord WG, Glenn GM, Turner M, Pavlovich CP, Schmidt LS, Walther MM, Choyke P, Weirich G, Hewitt SM, et al. 2002. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11:393-400.
99. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. 2006. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3: e13. doi:10.1371/journal.pmed.0030013.
100. Zhuang Z, Park WS, Pack S, Schmidt LS, Pak E, Pham T, Weil RJ, Candidus S, Lubensky IA, Linehan WM, et al. 1998. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20:66-69.